ProQR Therapeutics N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRQR research report →
Range $3 – $3
Price Chart
About the company
ProQR Therapeutics N. V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders.
- CEO
- Daniel Anton de Boer
- IPO
- 2014
- Employees
- 166
- HQ
- Leiden, ZH, NL
Get TickerSpark's AI analysis on PRQR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $239.05M
- P/E
- -4.91
- Fwd P/E
- 96.81
- PEG
- -0.84
- P/S
- 11.01
- P/B
- 2.69
- EV/EBITDA
- -2.67
- Div Yield
- 0.00%
- Gross Margin
- 92.33%
- Op Margin
- -232.71%
- Net Margin
- -228.29%
- ROE
- -68.44%
- ROIC
- -41.91%
Latest fiscal year · YoY change
- Revenue
- $15.28M-19.2%
- Gross Profit
- $12.68M-32.9%
- Op Income
- $-42,154,897
- Net Income
- $-40,519,110-45.9%
- EPS
- $-0.38-11.8%
- OCF Growth
- -45.1%
- FCF Growth
- -42.3%
- 52W High
- $3.10
- 52W Low
- $1.33
- 50D MA
- $1.76
- 200D MA
- $1.79
- Beta
- 0.03
- RSI (14)
- 71
- Avg Volume
- 1.02M
No earnings-call transcripts are available for PRQR yet.
- Free Float
- 61.1%
- Shares Outstanding
- 105.31M
- Float Shares
- 64.32M
of shares held by institutions
67 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Two Sigma Advisers, LP | 452.40K | ▲ 223.80K |
| Cubist Systematic Strategies, LLC | 52.19K | ▲ 48.13K |
Held by 15 ETFs
Biggest fund positions in PRQR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | de Boer Daniel Anton | buy | 200,000 |
| Jul 17, 26 | Filius Bart | buy | 150,000 |
| Jul 9, 26 | de Boer Daniel Anton | buy | 150,000 |
| Jul 7, 26 | de Boer Daniel Anton | buy | 150,000 |
| Jun 2, 26 | Hinsch Gylvin Lykke | other | 14,595 |
| Jun 26, 26 | Filius Bart | buy | 150,000 |
| Jun 2, 26 | Hinsch Gylvin Lykke | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 5,815 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRQR coverage
Recent articles, reports, and earnings notes.
No research on PRQR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRQR report →ProQR Announces Second Quarter 2026 Operating and Financial Results
globenewswire.com · Aug 13
Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)
defenseworld.net · Aug 11
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of “Moderate Buy” from Analysts
defenseworld.net · Aug 4
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
seekingalpha.com · Jul 4
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
globenewswire.com · Jun 25
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
globenewswire.com · Jun 25
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
globenewswire.com · Jun 25
ProQR Announces First Quarter 2026 Operating and Financial Results
globenewswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.